COGT - Company ID 0001622229
The table below shows Cogent Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$86.88M | -$66.51M | -$52.53M | -$39.52M | -$28.33M | -$11.37M |
| Capital expenditure | $449.00K | $547.00K | $70.00K | $1.10M | $441.00K | - |
| Investing cash flow | -$36.46M | $69.38M | $1.04M | $59.88M | -$441.00K | - |
| Dividends paid | - | - | - | - |
Cogent Biosciences, Inc. reported operating cash flow of -$264.44M for fiscal year 2025. That is down 27.3% from -$207.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$25.84M (FY 2017) to -$264.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $52.54M | $24.97M | $214.06M | $445.00K | $138.00K | -$85.00K |